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Abstract--Cytokine release from irradiated cells has been postulated to start soon 
after irradiation preceding detectable clinical and pathological manifestation of lung 
injury. The expression of transforming growth factor beta (TGFI3), a fibrogenic and 
radiation-inducible cytokine, was studied from 1-16 weeks after the 15 and 30 Gray 
(Gy) of thoracic irradiation to rats. Thoracic irradiation caused an increase in TGF/3 
protein in bronchoalveolar lavage (BAL) fluid peaking at 3-6 weeks as compared to 
sham-irradiated control rats. Steady state TGF~ mRNA expression as shown by whole 
lung northern blot assay paralleled the TGFI3 protein expression in BAL fluid. The 
peak of TGFI3 protein increase in BAL fluid between 3 and 6 weeks coincided with 
the initial influx of inflammatory cells in BAL fluid, but preceded histologically 
discernable pulmonary fibrosis that was not apparent until 8-10 weeks after irradia- 
tion. In conclusion, TGFt3 and rnRNA and protein upregulation preceded the radia- 
tion-induced pulmonary fibrosis, suggesting a pathogenetic role in the development 
of radiation fibrosis. 
I N T R O D U C T I O N  
Ionizing radiation produces free radicals that cause oxidative injury to cell organ- 
elles in susceptible cells (1). The outcome of  radiation at an organ level, how- 
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ever, depends not only on the individual cell response but also on the autocrine, 
paracrine, and endocrine interaction of the various types of radiated cells via 
the release of cytokines and growth factors (2, 3). Ionizing radiation to the 
normal lung tissue causes radiation pneumonitis and fibrosis that typically occur 
after 1-3 months of a latent period during which clinical pathological manifes- 
tations are not detectable (1). The importance of molecular events during this 
clinically silent latent period after thoracic irradiation has been only recently 
appreciated (4). Release of cytokines and growth factors during the latent period 
are postulated to be crucial in the development of the later lung injury (4). 
However, the kinetics of the in vivo expression of cytokines in the latent phase 
or in the later stage accompanying detectable lung injury is still largely unknown. 
A better understanding of cytokine interactions in radiation injury may prove 
clinically useful as suggested by a study demonstrating the beneficial effect ot 
interferon gamma treatment in a rat radiation pneumonitis model (5). 
TGF/3 exerts multiple effects on mesenchymal cells including enhancement 
of the expression of both fibronectin and collagen by fibroblasts. TGFI3 has been 
reported to be inducible and activated by radiation of the liver and mammary 
gland (2, 6). Changes in plasma TGF/3 levels during radiotherapy have been 
reported as a predictor of the risk of developing radiation pneumonitis in humans 
(7). Early alterations in TGF/3 gene expression have been reported as an indi- 
cator for later fibrosis in a mouse lung radiation model (8). 
The purpose of the present study was to investigate the expression of TGFI3 
in the evolution of radiation-induced lung injury in vivo. The kinetics of inflam- 
matory cell exudation in BAL fluid and histologic changes were also studied 
and correlated with the kinetics of TGF/3 expression. 
M E T H O D S  
General Experimental Design. Rats were divided into three groups receiving thoracic irra- 
diation at doses of: 1) 15 Gy in both lungs, 2) 30 Gy in fight lung only or in both lungs, and 3) 
sham irradiation. At various time points ranging from 1 to 16 weeks after the 15 Gy, 30 Gy 
irradiation (n = 3, each time point) or sham-irradiation (n = 2, each time point), rats were sacrificed 
for BAL to enumerate inflammatory cell counts and to measure cytokine levels. All lungs were 
histologically examined after the BAL procedure. Whole lung northern blot assay was performed 
with a naive rat and rats (n = 4) receiving 30 Gy of radiation in both lungs to determine TGF~ 
mRNA expression. 
Thoraeic Irradiation. Male Sprague-Dawley rats weighting approximately 225 grams were 
anesthesized by intraperitoneal injection of sodium pentobarbital at a dose of 1 mg per kg of body 
weight. The rats were treated with a single anterior field utilized either a 6 or 10 MV linear 
accelerator photon beam. A dose of 15 or 30 Gy was delivered at a rate of 1.5 Gy/minute to the 
level of midplane (approximately 1.5 cm). All rats in 15 Gy dose group received whole lung 
irradiation, and all rats in 30 Gy group except 4 rats for molecular biology received fight lung 
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irradiation only. A sufficient thickness of tissue equivalent material was added in order to provide 
electronic equilibrium, thus the total dose gradient was approximately _+6% for the 10 MV photon 
energy and _+7% for the 6 MV. The rats were secured supine with a 4 cm • 4 cm radiation field 
encompassing both lungs or with a 2 cm • 4 cm radiation field including the right lung only. The 
animals were visually monitored for movement throughout the treatment period. Sham irradiated 
rats received the same anesthesia and manipulation but were not exposed to radiation. After radiation, 
all rats were given prophylactic tetracyclin in chlorinated drinking water (500 mg/100 m 1' and had 
free access to Purina Rat Chow (Ralston Purina Company, St. Louis, Missouri). 
Bronchoalveolar Lavage. At various time points ranging from 1-16 weeks after radiation 
treatment, rats were sacrificed and BAL was performed to enumerate the absolute numbers of 
inflammatory cells in the intraalveolar exudate as previously described with minor modifications 
(9). In the rats receiving 30 Gy of irradiation in the fight hemithorax, separate BAL was performed 
in the fight and left lungs by clamping the main bronchi alternately. Each lung was lavaged with 7 
ml of Hank's essential medium, instead of 14 ml for the whole lung BAL, with recovery of 
approximately 5 ml. The absolute numbers of total nucleated cells in BAL fluid were counted with 
an automated cell counter (Sysmax, Irvine, California). Differential counts of leukocyte subsets 
were determined by counting 200 nucleated blood cells after modified Wright-Giemsa staining 
(DiffQuik; Scientific Products, McGaw Park, Illinois) on cytospin preparation. The absolute num- 
bers of each leukocyte subset were calculated by multiplying the total and differential and were 
expressed as the mean _+ one-standard deviation of the mean. The probability value was determined 
by the t-test (Systat, Evanston, Illinois). 
Cytokine Assay. Cell free BAL supematants were used to measure protein levels of TGF/3. 
TGF/3 protein level was measured by sandwich enzyme-linked immunoabsorbent assay (ELISA) 
using TGF/31-specific turkey and rabbit polyclonal antibodies as previously described (10). Data 
obtained by serial dilution of BAL specimens (3 dilutions in triplicate) was presented as the mean 
_+ one standard deviation of the mean per ml of BAL. The probability value was determined by 
the t-test (Systat, Evantson, Illinois). 
Northern Blot Assay. The mRNA expression of TGFt3 was examined in rats at time 0 (naive 
rat) and at 1, 2, 3, and 4 weeks after 30 Gy irradiation to the whole lung field. While the heart was 
still beating after deep anesthesia with excessive ether, the lungs were removed, immediately frozen 
in liquid nitrogen, and stored in - 7 0 ~  freezer. At the time of the assay, lungs were thawed and 
homogenized for 30 seconds with a tissue homogenizer. Total cellular RNA was extracted by 
guanidine isothiocyanate/cesium chloride method (1). The yield and purity of RNA was quantitated 
by measuring the ratio of the absorbences at 260 and 280 nm. Successful isolation of undegraded 
RNA was monitored by mini-gel electrophoresis in the presence of ethidium bromide and exami- 
nation of the sharpness of the 28S and 18S ribosomal RNA bands under ultraviolet light. Standard 
northern blotting was performed by electrophoretic separation of total RNA (10 #g/lane) on a 1.0% 
agarose/1.1M formaldehyde gel followed by blotting of the RNA onto a nylon membrane (Duralon- 
UVT~; Stratagene, La Jolla, California). RNA blots were hybridized with probes corresponding to 
the rat TGF/31 cDNA cloned as previously described (12). After hybridization, the blots were washed 
at 65~ for 15 minutes, twice with 2X SSC and 0.1% SDS and twice with 0.2X SSC and 0.1% 
SDS. 
Histology and Immunohistochemistry. After BAL procedure all lungs were processed for 
histologic evaluation. A midsagittal section of the fight and left lung encompassing the largest 
surface area was taken. Formalin-fixed paraffin embedded lung sections were examined to determine 
the extent of pneumonitis and fibrosis with hematoxylin eosin and masson-trichrome stainings. 
Formalin-fixed paraffin-embedded lung tissue was used for immunohistochemical localization of 
TGF/3 and surfactant apoprotein in selected blocks. Antibodies to TGF/3 detecting extracellular 
secreted form of TGF/31 (gift of Dr. K. Flanders at NCI; 1 : 1,000 dilution) and surfactant apoprotein 
SP-B (gift of Dr. J. Whisett at Children's Hospital, Cincinnati, Ohio; 1 : 100 dilution) were used 
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as primary antibodies. Standard avidin-biolin complex (ABC) immunohistochemical slaining was 
performed with biotinylated secondary antibody and 3'3 diaminobenzidine tetrachloride (Sigma, St. 
Louis, Missouri) as chromogen (13). 
R E S U L T S  
TGF/3 immunoassay of the BAL fluids showed an increase in TGFB between 
3 and 8 weeks, peaking at 3-6 weeks, as compared to the sham-irradiated control 
rats (p = 0.03, pooled values at 3-8 weeks after 30 Gy irradiation) (Figure l). 
Constitutive TGF~t gene expression was detected in aaive rat lungs at time 0 
(Figure 2)~ The upregulation of steady-state TGF~ mRNA expression was dis- 
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Fig. 1. TGF~3 protein increase in BAL fluid was radiation dose-dependent and peaked at 3 to 6 
weeks after thoracic irradiation as shown by sandwich enzyme-linked immunoabsorbant assay. 
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Fig. 2. Whole lung northern blot assay showed steady-state TGFfl mRNA upregulation as early as 
1 week after 30 Gy of thoracic irradiation. TGFfl mRNA expression gradually increased till 4 weeks 
as compared to the constitutive expression at time 0 before radiation. 
cemable as early as 1 week and remained increased until 4 weeks after the 30 
Gy radiation as shown by whole lung northern blot assay (Figure 2). 
After 30 Gy irradiation to the right hemithorax, inflammatory cell counts 
in BAL fluid from the right lung were compared against the cell counts from 
the left lung that was not exposed to radiation (Figure 3). The greatest increase 
in PMN counts was detected mostly between 3 and 10 weeks after the radiation 
as compared to the unradiated left lungs (p < 0.0001, pooled values at 3 to 10 
weeks). Elevated lymphocyte counts were also observed from 3 to 10 weeks 
after radiation as compared to the left lungs (p = 0.001, pooled values at 3 to 
10 weeks). There was no significant difference in macrophage/monocyte counts 
throughout the course except for a slight early decline at 1 week (data not 
shown). The BAL cell counts in rats with 15 Gy radiation showed similar 
kinetics of  intraalveolar PMN and lymphocyte exudation, but lesser in extent 
(data not shown). Sham-irradiated rats did not show any increase in the BAL 
inflammatory cell counts over time (data not shown). 
Histologically,  the radiated fight lung showed no remarkable changes until 
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Fig. 3. Neutrophil and lymphocyte counts in BAL fluids of the right lungs were increased mostly 
between 3 to 10 weeks after 30 Gy irradiation as compared to the non-radiated left lungs of the 
same rats. 
3 weeks after 30 Gy irradiation at which time perivascular edema was first 
noticeable. Intraalveolar edema and inflammatory cell infiltration developed after 
4 weeks, became most prominent at 6 to 8 weeks (Figure 4), and subsided at 
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gen fibrosis replaced the earlier pneumonitis at 10-16 weeks after 30 Gy thoracic 
irradiation (Figure 5). With 15 Gy irradiation, both inflammatory and fibrotic 
changes were much less pronounced, correlating with the lower inflammatory 
cell counts and TGF/3 protein levels in BAL fluids. 
Immunoreactive TGF/3 was constitutively present in sham-irradiated or non- 
irradiated left lung localized at the connective tissue around bronchioles and 
vessels. At 4 weeks after irradiation, TGFB immunoreactivity was also noted 
in the perivascular and peribronchiolar area but in somewhat patchy fashion. At 
later time points, immunoreactive TGF/3 was mainly localized in thickened 
alveolar septa and within areas of fibroblastic proliferation (Figure 6). The irreg- 
ular size and shape of type II pneumocytes in fibrotic lungs as compared to non- 
irradiated lungs were demonstrated by anti-surfactant staining (Figures 7a and 
7b). 
DISCUSSION 
Rats receiving 30 Gy whole lung irradiation in preliminary experiments 
invariably died by 9 weeks after the radiation. Histologic sections of the lungs 
after death showed marked intraalveolar edema, inflammatory cell infiltration, 
and early fibrosis. In order to study the later phase of radiation fibrosis in the 
lung and to avoid any cardiac irradiation effects, we treated only the right 
hemithorax with 30 Gy irradiation for the BAL cytokine measurement and cell 
counts. However, the histologic changes in whole lung- and right lung-irradiated 
rats appeared similar during the initial 9 week-period. 
The pathogenetic role of TGF/3 has been studied by Phan et al and several 
other investigators in a model of bleomycin-induced fibrosis (14-20). Steady- 
state TGF/3 mRNA expression is maximally elevated 1 week after bleomycin 
exposure, preceding the rise in gene expression for procollagens, fibronectin, 
and laminin in this model (21). In our thoracic irradiation model, the upregu- 
lation of TGF/~ mRNA and protein expression also preceded histologically rec- 
ognizable fibrosis, suggesting a pathogenetic role for TGF/3 in radiation induced 
pulmonary fibrosis, A marked increase in TGF~ protein level in lung homog- 
enates has been reported in the bleomycin-induced fibrosis model (22). Immu- 
nohistochemical staining using CC polyclonal antibody that detects secreted 
form of TGF/3 showed that TGF/3 was mainly localized to the site of fibrosis 
as previously reported by Limper et al. (23). Alveolar macrophages and bron- 
chial epithelial cells in the present study did not show significant TGF~ staining 
in contrast to a previous report (24), probably because the CC antibody only 
detects the secreted form of TGFI3. Immunoreactive TGF/3 in fibrotic areas was 
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suggested that secreted TGF/3 diffuses away from the producing cells and is 
concentrated in extracellular matrix of fibrotic lesions such as idiopathic pul- 
monary fibrosis and bronchiolitis obliterans organizing pneumonia (23). 
Light microscopic and ultrastructural changes in radiation induced lung 
injury have been well studied in the past (25). A quantitative morphometric 
study at 12 to 26 weeks after unilateral 30 Gy thoracic irradiation showed a 
decrease in type I and II pneumocytes and capillary endothelial cells and an 
increase in interstitial cells and matrix as the morphologic basis for functional 
loss in the radiated lung (26). The lung cells most susceptible to radiation include 
the type II pneumocytes, endothelial cells, and alveolar macrophages (1, 24). 
Type II pneumocyte damage has been demonstrated by ultrastmctural study as 
early as 1 hour after radiation and results in the immediate release of surfactant 
(1). Plasma surfactant apoprotein level has been shown to increase after radiation 
in a dose-dependent manner and has been proposed as a marker for the later 
development of pulmonary fibrosis (27). Pretreatment with keratinocyte growth 
factor (KGF), a potent type II pneumocyte growth factor in vivo (28), has been 
shown to prevent the bleomycin-induced lung fibrosis in rats (29), suggesting 
that type II pneumocytes are important in the regulation of development of 
fibrosis. The abnormality of type II pneumocytes found in our study might be 
related to the pathogenesis of radiation-induced fibrosis. 
In conclusion, the early expression of TGF/3 in the course of radiation- 
induced lung injury is consistent with the current concept that release of cyto- 
kines such as TGF/3 after radiation leads to the later development of fibrosis. A 
better understanding of the roles of individual cytokines in radiation lung injury 
could provide clinically useful means to prevent the late fibrosis by specific and 
early intervention of these molecules. 
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